In the last trading session, 2.53 million Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares changed hands as the company’s beta touched 1.32. With the company’s per share price at $0.22 changed hands at $0.01 or 7.14% during last session, the market valuation stood at $6.04M. SYRS’s last price was a discount, traded about -3527.27% off its 52-week high of $7.98. The share price had its 52-week low at $0.18, which suggests the last value was 18.18% up since then. When we look at Syros Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 4.92 million shares, with the 3-month average coming to 9.31 million.
Analysts gave the Syros Pharmaceuticals Inc (SYRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.33. If we narrow down to specifics, the data shows that 0 out of 7 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended SYRS as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Syros Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.71.
Syros Pharmaceuticals Inc (NASDAQ:SYRS) trade information
Instantly SYRS was in green as seen at the end of in last trading. With action -2.22%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -2.09%, with the 5-day performance at -2.22% in the red. However, in the 30-day time frame, Syros Pharmaceuticals Inc (NASDAQ:SYRS) is -7.79% down. Looking at the short shares, we see there were 1.57 million shares sold at short interest cover period of 0.07 days.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 95.6% from its current market value. According to analyst projections, SYRS’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -2172.73% plunge from its current level, while the stock would need to soar -2172.73% for it to hit the projected low.
Syros Pharmaceuticals Inc (SYRS) estimates and forecasts
Data shows that the Syros Pharmaceuticals Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -96.24% over the past 6 months, a 65.53% in annual growth rate that is considerably higher than the industry average of 16.40%. Year-over-year growth is forecast to reach -100.00% down from the last financial year.
The company’s revenue for the corresponding quarters a year ago was 386k. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -100.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.16%. The 2025 estimates are for Syros Pharmaceuticals Inc earnings to increase by 72.86%.
SYRS Dividends
Syros Pharmaceuticals Inc is expected to release its next quarterly earnings report in February.
Syros Pharmaceuticals Inc (NASDAQ:SYRS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.74% of Syros Pharmaceuticals Inc shares while 75.59% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 76.15%.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 654.18 shares estimated at $0.15 million under it, the former controlled 2.44% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.96% of the shares, roughly 257.63 shares worth around $57967.0.
